用细粒囊蚴液的免疫疗法抑制小鼠结肠癌细胞生长。
Inhibition of mouse colon cancer growth following immunotherapy with a fraction of hydatid cyst fluid.
发表日期:2023 Mar 15
作者:
Shahla Rostamirad, Shima Daneshpour, Mohammad Reza Mofid, Alireza Andalib, Abbasali Eskandariyan, Somayeh Mousavi, Hossein Yousofi Darani
来源:
Parasites & Vectors
摘要:
细粒棘球绦虫的幼虫期是囊虫,位置在人类和家畜的内脏器官中。有些科学证据表明寄生虫感染能够对某些癌症形式产生抗肿瘤活性。在本研究中,调查了囊虫蚴液的一部分对BALB/c小鼠结肠癌肿瘤的影响。
在这项实验性工作中,将六组小鼠注射了小鼠结肠癌细胞。当小鼠中出现肿瘤增长迹象时,组1-4分别注射了囊虫蚴液、78kDa分子量的部分、活性囊尾蚴和卡介苗。第五组只注射了明胶悬液,第六组则没有任何注射。比较所有组的肿瘤大小,并对小鼠的血液样本进行血清细胞因子水平评估。
在注射了囊虫蚴抗原、特别是囊虫蚴液的一部分的小鼠中,肿瘤大小比对照组小,且病例组和对照组的肿瘤大小差异具有统计学意义。
本研究的结果表明,注射小鼠囊虫蚴液的一部分可以显著抑制小鼠结肠癌的生长,这种抑制可能与免疫应答对这些抗原的影响有关。
版权所有©2023 Elsevier Inc.发表
Hydatid cyst is the larval stage of the tape worm Echinococcus granulosus which is located in human and livestock viscera. There are some scientific evidences indicating that parasitic infections induce antitumor activity against certain types of cancers. In this study, the effects of a fraction of hydatid cyst fluid on colon cancer tumor in BALB/c mice were investigated.In this experimental work six groups of mice were challenged with mouse colon cancer cells. 5 days later when the sign of tumor growth in mice was seen, group 1-4 were injected with hydatid cyst fluid, the 78 kDa fraction, live protoscolices and BCG respectively. Group five was injected with alum alone and the sixth group left intact without any injection. The size of the tumor was measured and compared in all groups. Then blood samples of mice were evaluated for serum cytokine levels.In mice injected with hydatid cyst antigens especially a fraction of hydatid cyst fluid, tumor size was smaller than the that of control groups and the difference of tumor size in cases and control groups was statistically significant.The results of this study showed that injection of mice with a fraction of hydatid cyst fluid significantly inhibits the growth of mouse colon cancer and this inhibition may be related to effect of immune response to these antigens.Copyright © 2023. Published by Elsevier Inc.